Mankind Pharma on Monday announced its foray into the agri-tech segment, with plans to invest up to Rs 200 crore in the first two to three years.
The company has set up a new arm Mankind Agritech Pvt Ltd, which will offer a variety of crop care solutions to Indian farmers, including weedicides, insecticides, fungicides, plant growth regulators and biologicals, Mankind Pharma said in a statement.
“We are happy to announce our launch in the agritech domain with long-term investment plans, with an initial (Rs) 150 to (Rs) 200 crore capex infusion in the first two to three years,” Mankind Pharma Managing Director and Vice-Chairman Rajeev Juneja said.
Asserting that technology is playing a crucial role in ensuring the growth of the agriculture sector in India, he said, “Agritech has the potential to scale up the agricultural industry through technological intervention. If the farmers get the right products and tools they would be in a position to make an informed decision of using input and right technology”.
The new vertical will be headed by Indian agrochemical industry veteran Partha Sengupta, who was the national marketing head and part of the senior leadership team at Dhanuka Agritech Ltd, overseeing marketing operations in India, Bangladesh and Nepal, the company said.
The decision behind foraying into this division is to assist Indian farmers by providing new-age technologies and helping farmers for the betterment of the rural sector, it added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);fbq(‘init’,’550264998751686′);fbq(‘track’,’PageView’);
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YHNOZI2ORZKCNDGE4C4HZ7DF2E.jpg)
